A Case Report on Metastatic Ileal Neuroendocrine Neoplasm to the Breast Masquerading As Primary Breast Cancer: A Diagnostic Challenge and Management Dilemma
Overview
Authors
Affiliations
Rationale: Metastatic neuroendocrine neoplasms (NENs) to the breast are very rare entities comprising only 1% to 2% of all metastatic breast tumors. In this article, we describe a case of a neuroendocrine ileal neoplasm metastatic to breast and liver, with breast metastatic tumor to be the initial manifestation of the disease.
Patient Concerns: We herein report a rare case of a female patient admitted to our department with a palpable painful mass on her left breast.
Diagnosis: The surgical and histological investigation revealed a metastatic neuroendocrine neoplasm to the breast originated from terminal ileum.
Interventions: A left lumpectomy, right hemicolectomy, cholecystectomy, left hepatectomy along with liver metastasectomies (V, VI, VIII) plus radiofrequency ablation of lesions to the right liver lobe plus standard lymphadenectomy was performed.
Outcomes: Considering the advanced stage of the disease, the patient received an adjuvant therapy of somatostatin analog plus everolimus. Under the guidance of oncological consultation, patients follow-up with CT and MRI scan and clinical re-evaluations in the first 3 and 6 months, substantiates no evidence of recurrence and she presents herself asymptomatic.
Lessons: An appropriate level of suspicion and selective immunohistochemistry in these cases, particularly where no prior history of a known primary neuroendocrine neoplasm occurs, may help to diagnose a previously undetected neuroendocrine tumor elsewhere in the body and provide guidance for the appropriate treatment selection.
Neuroendocrine Tumor Metastases to the Breast: A Case Report and Review of the Literature.
Urrego Diaz J, Gonzalez M, Romero-Rojas A, Strosberg J, Jimenez-Vasquez P Cureus. 2023; 15(6):e40703.
PMID: 37485220 PMC: 10359153. DOI: 10.7759/cureus.40703.
The Application of Whole-Process Case Management in Patients with Triple-Negative Breast Cancer.
Zhao Y, Zhu R, Bai J, Li J, Jia X, Wang P J Oncol. 2022; 2022:1794288.
PMID: 35342395 PMC: 8942700. DOI: 10.1155/2022/1794288.